arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Ironwood Pharmaceuticals, Inc.

IRWD Health Care Biotechnology: Pharmaceutical Preparations
$4.26
Today
as of Sep 4, 16:50 ET
Last 30 days +12.11% Jul 28 → Sep 04
$3.49 $3.74 $3.99 $4.24 $4.49 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$4.26
High
$4.33
Low
$4.22
Volume
$829,288
Avg Vol
$3M
Mkt Cap
$674M
P/E (TTM)
7.75
Beta
—
52w High
$5.78
52w Low
$1.05
Div Yield
—
Shares Out
$165M

Recent Press Releases & News last 60 days · 11 items

Sep 3 · 20:05 PR Business Wire
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Aug 13 · 17:43 Motley Fool
Ironwood (IRWD) Q2 2026 Earnings Call Transcript
Aug 7 · 12:30 Moby
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
▸ Show all 11 press releases & news Free account →

Overview

52-week range
$1.05
$5.78
68% of range
Avg surprise (last 3)
+287.6%
Avg reaction (last 2)
-14.4%
0% positive
Latest IV / EM
240%
EM ±37.6% · $5 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.14$-0.03$0.08$0.20$0.31 Actual $-0.14Est $-0.05Actual $0.14Est $-0.02Actual $0.24Est $0.07Actual $0.31 Mar/2025Jun/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-37M$2M$41M$80M$119M Mar 25Jun 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $0.31 — — — — financials
Thu May 7, 2026Mar/2026 $0.24 $0.07 +242.9% +271.4% -13.7% earnings
Thu Aug 7, 2025Jun/2025 $0.14 $-0.02 +800.0% — — earnings
Wed May 7, 2025Mar/2025 $-0.14 $-0.05 -180.0% — -15.1% earnings

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$113M$107M——$85M$41M——
Cost of revenue————————
Gross profit————————
Operating income$79M$73M—$75M$45M$-29M—$26M
Net income$51M$41M——$24M$-37M——
EPS (diluted)$0.31$0.24——$0.14$-0.23——

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$79M$220M$215M$140M$93M$108M$89M$88M
Inventory————————
Total current assets$199M$332M$274M$274M$192M$161M$182M$179M
Total assets$285M$435M$397M$396M$343M$327M$351M$390M
Long-term debt———$200M$199M$199M$199M$199M
Total liabilities$447M—$659M—————
Total equity$-162M$-217M$-262M$-264M$-308M$-334M$-301M$-311M

Implied volatility — last 90 days

23%373%723%1073%1423% Jun 07 — IV 393% · EM ±54.4%Jun 08 — IV 426% · EM ±56.2%Jun 09 — IV 438% · EM ±54.9%Jun 10 — IV 329% · EM ±38.8%Jun 11 — IV 524% · EM ±57.9%Jun 12 — IV 549% · EM ±56.2%Jun 15 — IV 976% · EM ±70.6%Jun 16 — IV 948% · EM ±56.0%Jun 17 — IV 1326% · EM ±55.4%Jun 19 — IV 169% · EM ±37.4%Jun 22 — IV 160% · EM ±33.4%Jun 23 — IV 292% · EM ±59.7%Jun 24 — IV 304% · EM ±60.9%Jun 25 — IV 292% · EM ±57.3%Jun 26 — IV 278% · EM ±53.1%Jun 29 — IV 223% · EM ±39.5%Jun 30 — IV 235% · EM ±40.5%Jul 01 — IV 262% · EM ±43.7%Jul 02 — IV 214% · EM ±34.6%Jul 03 — IV 222% · EM ±34.6%Jul 06 — IV 136% · EM ±18.8%Jul 07 — IV 24% · EM ±3.2%Jul 08 — IV 50% · EM ±6.3%Jul 09 — IV 36% · EM ±4.3%Jul 10 — IV 222% · EM ±24.5%Jul 13 — IV 412% · EM ±34.4%Jul 14 — IV 655% · EM ±47.4%Jul 15 — IV 847% · EM ±50.0%Jul 16 — IV 1423% · EM ±59.4%Jul 20 — IV 71% · EM ±16.9%Jul 21 — IV 95% · EM ±22.0%Jul 22 — IV 99% · EM ±22.6%Jul 23 — IV 88% · EM ±19.9%Jul 24 — IV 100% · EM ±22.0%Jul 27 — IV 101% · EM ±21.1%Jul 28 — IV 79% · EM ±16.1%Jul 29 — IV 122% · EM ±24.5%Jul 30 — IV 98% · EM ±19.2%Jul 31 — IV 83% · EM ±16.0%Aug 03 — IV 112% · EM ±19.8%Aug 04 — IV 109% · EM ±18.7%Aug 05 — IV 109% · EM ±18.2%Aug 06 — IV 87% · EM ±14.1%Aug 07 — IV 82% · EM ±12.9%Aug 10 — IV 71% · EM ±9.9%Aug 11 — IV 106% · EM ±14.0%Aug 12 — IV 106% · EM ±13.2%Aug 13 — IV 78% · EM ±9.2%Aug 14 — IV 100% · EM ±11.1%Aug 17 — IV 192% · EM ±16.1%Aug 18 — IV 176% · EM ±12.8%Aug 19 — IV 291% · EM ±17.2%Aug 20 — IV 318% · EM ±13.3%Aug 28 — IV 120% · EM ±23.0%Aug 31 — IV 128% · EM ±22.7%Sep 01 — IV 197% · EM ±33.9%Sep 02 — IV 182% · EM ±30.4%Sep 03 — IV 216% · EM ±35.0%Sep 04 — IV 240% · EM ±37.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in